Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Goxaparin - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Goxaparin

Approved

STANDARD

Goxaparin

Brawn Laboratories Ltd🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 5b1bb770d3dc8852
Company: Brawn Laboratories Ltd
Type: Standard

Approval Details

Approval Id: 5b1bb770d3dc8852
Drug Approval Philippines Name: Goxaparin
Product Name: Goxaparin
Registration Number: BRP-040-06
Brand Name: Goxaparin
Generic Name: Enoxaparin sodium
Dosage Form: Solution For Injection (SC)
Dosage Strength: 6000 IU anti-Factor Xa (equivalent to 60 mg) / 0.6 mL
Manufacturer: Brawn Laboratories Ltd
Importer: Ambica International Corporation
Distributor: Applied Pharmaceutical Distribution Inc.
Issuance Date: 31 March 2025
Expiry Date: 31 March 2037
Pharmacologic Category: Antithrombotic Agents
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

5b1bb770d3dc8852

Type

Standard

Back to Philippines FDA Approvals